BTIG upgraded T2 Biosystems (NASDAQ:TTOO) to “neutral” from “sell,” saying the shares have fallen below a prior $4 price target. The stock closed at $3.98 on May 5.Read More
Leerink resumed coverage of T2 Biosystems (NASDAQ:TTOO) with a “market perform” rating and $5 price target. The stock finished at $6.31 on Wednesday.
“While we view T2’s proprietary T2MR pathogen detection technology and large market opportunity favorably, we are inclined to stay on the sidelines until T2 delivers consistently on instrument placements and strings together a series of solid quarters in line with Street expectations,” writes analyst Puneet Souda.Read More